1Arnold DM, Julian JA, Walker IR, et al. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood, 2006,108 : 460-464.
2Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS, 2008,22 :2303-2311.
3Sajadi MM, Shakeri N, Talwani R, et al. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS, 2010, 24:1689-1695.
4Berenguer J, Gonzcilez-Garcia J, L6pez-Aldeguer J, et al. Pegylated interferon { alpha } 2a plus ribavirin versus pegylated interferon {alpha} 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infeeted patients. J Antimierob Chemother, 2009,63 : 1256-1263.
5Ragni MV, Nalesnik MA, Schillo R, et al. Highly active antiretroviral therapy improves ESLI)-free survival in HIV- HCV co-infection. Haemophilia, 2009,15 : 552-558.
